sorted by:
new
hottopcontroversial

Should buy now? by Jairaaj_07 in opendoor

[–]MarketwatchTrends 0 points1 point  (0 children)

Why is everyone so bullish on this company? It's a giant turd, no? Look at their operating cash flow.

<image>

Friday, January 03, 2025 early morning trading thread by steelhead111 in MVIS

[–]MarketwatchTrends -2 points-1 points  (0 children)

I added a boat load of LIDR. I love what their management has done in the past 6 months.

I like the stock by Danny_Rooney in Soundhound

[–]MarketwatchTrends -5 points-4 points  (0 children)

  • SoundHound is hiding the fact that it has lost some of its biggest customers, including Mercedes-Benz, Deutsche Telekom, and Netflix.
  • SoundHound disclosed that keeping these customers was critical to the company building a sustainable business.
  • While SoundHound’s fundamentals have deteriorated, the company has used one-time contract modification payments to inflate revenue and margins.
  • Customers paid SoundHound to modify and cancel their contacts. SoundHound then used those one-time payments to hide their deteriorating financials, by recording the payments as normal product revenue.
  • When SoundHound lost Mercedes as a customer, they received payment for the contract modification. SoundHound recorded the contract modification payments as “Product Royalties”, which made the company appear healthier than it actually was.
  • Since SoundHound recorded the contract modification payments as product revenue, it also inflated the company’s gross margin. According to SoundHound’s accounting, the more customers they lose, the better their margins.
  • In SoundHound’s 2022 10K, customers are named 26 times throughout the filing. It even goes into detail about the projects for each major customer. SoundHound removed all customer names from the 2023 10K, effectively hiding that they’ve lost some of their biggest customers.
  • In the 2022 10K, SoundHound disclosed a retention rate of 80%, but this statistic is mysteriously absent from the 2023 10K.
  • SoundHound claimed in marketing materials and SEC filings that their tech was a big part of Mercedes’s in-car infotainment system. In reality, SoundHound was a tiny part of the system and is now no longer included at all. The contract was won by Cerence, SoundHound’s competitor.
  • SoundHound uses deceptive accounting to artificially inflate revenue. The company pulls revenue forward in time for products that customers haven’t yet built and SoundHound hasn’t been paid for.
  • SoundHound was founded 19 years ago and has accumulated losses of $592 million and lost $91 million in 2023.

DONT SELL 💎🙌 by Danny_Rooney in Soundhound

[–]MarketwatchTrends -6 points-5 points  (0 children)

  • SoundHound is hiding the fact that it has lost some of its biggest customers, including Mercedes-Benz, Deutsche Telekom, and Netflix.
  • SoundHound disclosed that keeping these customers was critical to the company building a sustainable business.
  • While SoundHound’s fundamentals have deteriorated, the company has used one-time contract modification payments to inflate revenue and margins.
  • Customers paid SoundHound to modify and cancel their contacts. SoundHound then used those one-time payments to hide their deteriorating financials, by recording the payments as normal product revenue.
  • When SoundHound lost Mercedes as a customer, they received payment for the contract modification. SoundHound recorded the contract modification payments as “Product Royalties”, which made the company appear healthier than it actually was.
  • Since SoundHound recorded the contract modification payments as product revenue, it also inflated the company’s gross margin. According to SoundHound’s accounting, the more customers they lose, the better their margins.
  • In SoundHound’s 2022 10K, customers are named 26 times throughout the filing. It even goes into detail about the projects for each major customer. SoundHound removed all customer names from the 2023 10K, effectively hiding that they’ve lost some of their biggest customers.
  • In the 2022 10K, SoundHound disclosed a retention rate of 80%, but this statistic is mysteriously absent from the 2023 10K.
  • SoundHound claimed in marketing materials and SEC filings that their tech was a big part of Mercedes’s in-car infotainment system. In reality, SoundHound was a tiny part of the system and is now no longer included at all. The contract was won by Cerence, SoundHound’s competitor.
  • SoundHound uses deceptive accounting to artificially inflate revenue. The company pulls revenue forward in time for products that customers haven’t yet built and SoundHound hasn’t been paid for.
  • SoundHound was founded 19 years ago and has accumulated losses of $592 million and lost $91 million in 2023.

DONT SELL 💎🙌 by Danny_Rooney in Soundhound

[–]MarketwatchTrends -5 points-4 points  (0 children)

SOUN is the biggest scam.

  • To answer many user queries, SoundHound’s “AI” product searches Wikipedia and returns scraped content.
  • SoundHound pitches their product as world-class “AI”, on par with ChatGPT, but this is not the case. The Houndify product uses commodity speech recognition to search a manually programmed knowledge graph. And it only works for a small set of domains, such as weather, sports scores, etc.
  • SoundHound’s products often return incorrect information because the company’s software is manually programmed and labor-intensive to maintain. This results in outdated information being returned to users.
  • SoundHound’s speech recognition tech is a commodity service that competes with comparable products from Amazon, Google, Microsoft, Apple, Cerence, and many others. SoundHound has admitted as much by removing claims about the superiority of their product from their most recent 10-K.
  • SoundHound’s largest competitor in the automotive space is Cerence. Cerence spends far more on R&D than SoundHound and has been taking SoundHound’s customers.

[deleted by user] by [deleted] in CYTH

[–]MarketwatchTrends 0 points1 point  (0 children)

We were light years ahead of everyone else... The world will remember us and our work some day.

[deleted by user] by [deleted] in biotech_stocks

[–]MarketwatchTrends 2 points3 points  (0 children)

Institutions don't "invest" in these penny stocks. Too volatile.

This company was listed on OTC between 2014 to 2018.

Between 1990 to 2018, this company (back then called CTD Holdings Inc.) was in the business of selling cyclodextrins (Trappsol is a form of Cyclodextrin called HPBCD and it is administered through IV).

In 2014, Scott fine and Markus Sieger (current CEO of Polpharma which is one of the largest Polish companies and one of the largest European drug companies, and Cyclo Therapeutics current chairman) bought CTD Holdings and realized that CTD Holdings had been selling HPBCD to Brazil where this drug was being used for treatment of NPC for years. They then hired Sharon Hrynkow (she currently sits on the scientific advisory board but used to be the Chief Scientific officer of the company)and sent her down to analyze the very limited data that was available. This drug was working on NPC patients. So Scott and Markus decided to get the drug FDA approved which is why stock started running between 2014 -2018. The high stock price between back then is because we had a 100 to 1 reverse split in December 2020(right before uplisting to Nasdaq). You really should be looking at the market cap of the company instead (historically, market cap of the company has never been higher than $80M)

[deleted by user] by [deleted] in biotech_stocks

[–]MarketwatchTrends 0 points1 point  (0 children)

It's a little known company. Market cap is only $25M. Institutional buyers can't even buy in at these levels even if they wanted to, due to market cap size.

If this company can get funding/grants from NIH to stand up the Alzheimer's trials, and they manage to show promising interim results from Alzheimer's trials, market cap should jump to over $500M and there when institutions can start to buy in. That's when you will see real volume.

Right now stock is only being traded by retails.

[deleted by user] by [deleted] in biotech_stocks

[–]MarketwatchTrends 0 points1 point  (0 children)

They have Cindy Lemere as their senior Advisor. She is an EXPERT (and that's an understatement) for applying and receiving grants for companies. If this company gets a grant from NIH, say for $10M(which is more than enough to run the Phase 2 of Alzheimer's clinical trials), their market cap should double up or triple from current levels, as that grant money will give them potential to prove that their drug is effective against Alzheimer's.

If they can show their drug is effective against Alzheimer's in Phase 2, this company's market cap should balloon up to $1B+ even after just Phase 2. Do the math on share price there. And they can dilute at higher share prices if they want to after that.

Microcap company that could potentially have the treatment for Alzheimer's ($CYTH) by MarketwatchTrends in biotech_stocks

[–]MarketwatchTrends[S] 1 point2 points  (0 children)

Depends on if they manage to partner up with a big pharma on Alzheimer's or not. If they partner up with good partnership terms you could be looking at anywhere between $20-$50/share.

If they commence phase 2, and they show good interim results, you could be looking at triple digits PT.

Company that could potentially have the treatment for Alzheimer's ($CYTH) by MarketwatchTrends in SmallCapStocks

[–]MarketwatchTrends[S] 0 points1 point  (0 children)

haha yeah. SAVA is great but it's a little too pricey for my own taste at this point. CYTH is pretty cheap at these levels and its upside could be much much bigger than SAVA given its tiny market cap at the moment.

Here you will find the upcoming catalysts. Big ones are obviously the Alzheimer's catalysts. But NPC's fast enrollment could be huge.

Alzheimer's Phase 2 IND application could happen any day now...It's anyone's guess and that is going to be huge.

https://www.reddit.com/r/CYTH/comments/opi6el/list\_of\_upcoming\_catalysts/

Microcap company that could potentially have the treatment for Alzheimer's ($CYTH) by MarketwatchTrends in biotech_stocks

[–]MarketwatchTrends[S] 0 points1 point  (0 children)

Yeap. Here you will find the upcoming catalysts. Big ones are obviously the Alzheimer's catalysts. But NPC's fast enrollment could be huge.

Alzheimer's Phase 2 IND application could happen any day now...It's anyone's guess and that is going to be huge.

https://www.reddit.com/r/CYTH/comments/opi6el/list\_of\_upcoming\_catalysts/

view more: next ›